Download
00701_2024_Article_6052.pdf 839,67KB
WeightNameValue
1000 Titel
  • Long-term outcome of surgically treated and conservatively managed Rathke cleft cysts
1000 Autor/in
  1. Schmutzer, Michael |
  2. Weller, Jonathan |
  3. Thorsteinsdottir, Jun |
  4. Schichor, Christian |
  5. Rachinger, Walter |
  6. Thon, Niklas |
  7. Ueberschaer, Moritz |
1000 Verlag Springer Vienna
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-01
1000 Erschienen in
1000 Quellenangabe
  • 166(1):159
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00701-024-06052-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984884/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objective</jats:title> <jats:p>Rathke cleft cysts (RCC) are benign lesions of the sellar region that require surgical treatment in case of visual deterioration or progression of the cyst. However, the natural course is often stable and asymptomatic.</jats:p> <jats:p>We aimed to investigate the characteristics of patients with cyst progression during follow-up (FU) and to compare the natural history of patients with RCC with patients who underwent surgery.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients with an MR morphologic cystic sellar lesion classified as RCC between 04/2001 and 11/2020 were included. Functional outcomes, including ophthalmologic, endocrinologic, and MRI data, were retrospectively analyzed and compared between surgically treated patients, patients on a “watch and wait” strategy (WWS), and patients on a WWS who underwent secondary surgery due to cyst progression.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>One hundred forty patients (median age 42.8 years) with RCC on MRI were identified. 52/140 (37.1%) underwent primary surgery. Of 88 patients (62.9%) with initial WWS, 21 (23.9%) underwent surgery for secondary cyst progression. Patients on the WWS had significantly smaller cyst volumes (<jats:italic>p</jats:italic> = 0.0001) and fewer visual disturbances (<jats:italic>p</jats:italic> = 0.0004), but a similar rate of hormone deficiencies (<jats:italic>p</jats:italic> = 0.99) compared with surgically treated patients preoperatively. Postoperatively patients suffered significantly more often from hormone deficiencies than WWS patients (<jats:italic>p</jats:italic> = 0.001).</jats:p> <jats:p>Patients who switched to the surgical group were significantly more likely to have preoperative T1 hyperintense signals on MRI (<jats:italic>p</jats:italic> = 0.0001) and visual disturbances (<jats:italic>p</jats:italic> = 0.001) than patients with continuous WWS. Postoperatively, these patients suffered more frequently from new hormonal deficiencies (<jats:italic>p</jats:italic> = 0.001). Endocrine and ophthalmologic outcomes in patients with primary and secondary surgery were comparable.</jats:p> <jats:p>Multivariate analysis showed that WWS patients were at a higher risk of requiring surgery for cyst progression when perimetric deficits (<jats:italic>p</jats:italic> = 0.006), hyperprolactinemia (<jats:italic>p</jats:italic> = 0.003), and corticotropic deficits (<jats:italic>p</jats:italic> = 0.005) were present.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Surgical treatment of RCC may cause new hormonal deficiencies, which are rare in the natural course. Therefore, the indication for surgery should be carefully evaluated. Hyperprolactinemia and corticotropic deficits were significant indicators for a secondary cyst progression in patients with RCC. However, a significant amount of almost 25% of initially conservatively managed cysts showed deterioration, necessary for surgical intervention.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Pituitaries
lokal Functional outcome
lokal Carcinoma, Renal Cell [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Transsphenoidal approach
lokal Retrospective Studies [MeSH]
lokal Kidney Neoplasms [MeSH]
lokal Endocrinological outcome
lokal Hyperprolactinemia [MeSH]
lokal Central Nervous System Cysts/diagnostic imaging [MeSH]
lokal Original Article
lokal Hormones [MeSH]
lokal Magnetic Resonance Imaging [MeSH]
lokal Cysts [MeSH]
lokal Secondary cyst progression
lokal Rathke cleft cysts
lokal Central Nervous System Cysts/surgery [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1387-0630|https://frl.publisso.de/adhoc/uri/V2VsbGVyLCBKb25hdGhhbg==|https://frl.publisso.de/adhoc/uri/VGhvcnN0ZWluc2RvdHRpciwgSnVu|https://frl.publisso.de/adhoc/uri/U2NoaWNob3IsIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/UmFjaGluZ2VyLCBXYWx0ZXI=|https://frl.publisso.de/adhoc/uri/VGhvbiwgTmlrbGFz|https://frl.publisso.de/adhoc/uri/VWViZXJzY2hhZXIsIE1vcml0eg==
1000 Hinweis
  • DeepGreen-ID: f6ef332f07c542d6afbf70074cd643c2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinik München |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinik München |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6494298.rdf
1000 Erstellt am 2025-02-04T02:13:18.735+0100
1000 Erstellt von 322
1000 beschreibt frl:6494298
1000 Zuletzt bearbeitet 2025-08-05T07:48:16.112+0200
1000 Objekt bearb. Tue Aug 05 07:48:16 CEST 2025
1000 Vgl. frl:6494298
1000 Oai Id
  1. oai:frl.publisso.de:frl:6494298 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source